Anteris Technologies Global Corp. filed its annual report on Form 10-K with the U.S. Securities and Exchange Commission for the fiscal year ended December 31, 2025, representing the company's first annual report following its initial public offering completed in December 2024.

Key Highlights

  • Exchange listing: Common stock, par value $0.0001 per share, is listed on The Nasdaq Global Market under the trading symbol AVR (NASDAQ:AVR), according to the filing's registered-securities table.
  • Shares outstanding: The filing reported 97,232,054 shares of common stock outstanding as of February 25, 2026.
  • Emerging growth company: The registrant is classified as an emerging growth company, a non-accelerated filer, and a smaller reporting company, as indicated by the filing's check-mark elections.
  • Core product: The company disclosed its primary investigational product is the DurAVR THV, described as a transcatheter heart valve made from a single piece of ADAPT tissue for the treatment of aortic stenosis.
  • Post-IPO reorganization: Prior to its December 2024 IPO, the company completed a series of reorganization transactions, with Anteris Technologies Global Corp. succeeding Anteris Technologies Pty Ltd as the reporting entity.
  • Principal offices: The registrant's principal executive offices are located at Toowong Tower, Level 3, Suite 302, 9 Sherwood Road, Toowong, QLD, Australia 4066.

DurAVR THV and ADAPT Tissue: Anteris Technologies' 2025 Annual Disclosure

Anteris Technologies Global Corp. (NASDAQ:AVR) submitted its fiscal year 2025 Form 10-K to the SEC, covering the period ended December 31, 2025. According to the filing, the company's central focus is the development of the DurAVR THV, a transcatheter heart valve described as "a novel, biomimetic (meaning human-like) valve made from a single-piece of native-shaped ADAPT tissue" intended for use in treating aortic stenosis, a condition the filing defines as "the narrowing of the aortic valve restricting the flow of blood from the left ventricle (lower chamber of the heart) to the aorta (main artery)."

The filing explains that ADAPT tissue is produced through the company's ADAPT tissue engineering process, which "transforms xenograft tissue (bovine heart tissue) into a durable bioscaffold which Anteris uses in its DurAVR THV to mimic human tissue in aortic valve replacement." The DurAVR THV is deployed using the ComASUR Delivery System, described as "the balloon expandable system which provides controlled deployment and accurate placement of the DurAVR THV, designed to achieve precise alignment with the heart's native commissures to achieve ideal valve positioning." The filing includes detailed technical definitions covering hemodynamic measures such as effective orifice area, Doppler velocity index, flow displacement, and flow reversal ratio, all of which the company uses to characterize valve performance in clinical contexts.

The company disclosed that it was not a public company as of the last business day of its most recently completed second fiscal quarter and therefore stated it "cannot calculate the aggregate market value of its voting equity held by non-affiliates as of such date." The filing identifies the registrant's Commission File Number as 001-42437 and its I.R.S. Employer Identification Number as 99-1407174. The 10-K spans four parts, covering business operations and risk factors in Part I, management's discussion and financial statements in Part II, governance and compensation in Part III, and exhibit schedules in Part IV.

What Was Disclosed

Anteris Technologies Global Corp. filed its first annual report on Form 10-K as a U.S. public company, covering fiscal year ended December 31, 2025. The filing encompasses the company's business description centered on the DurAVR THV device, risk factors, financial statements, management's discussion and analysis, executive compensation, and corporate governance disclosures. As of February 25, 2026, the registrant reported 97,232,054 shares of common stock outstanding, and confirmed its classification as an emerging growth company and smaller reporting company under applicable SEC rules.